Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 18,676,663	$ 5,420,708
Contracts and grants receivable	203,774	1,018,835
Research and development incentives receivable	361,096	444,043
Prepaid expenses and other current assets	225,473	609,739
Total current assets	19,467,006	7,493,325
Security deposit	22,777	22,757
Office furniture and equipment, net of accumulated depreciation of $158,769 and $135,038, respectively	23,510	36,093
Deferred issuance cost	53,523	39,324
Intangible assets, net		19,699
Right-of-use lease assets	228,027	125,412
Research and development incentives receivable	73,142
Other assets	23,250	38,750
Total assets	19,891,235	7,775,360
Current liabilities:
Accounts payable	2,129,844	2,735,442
Accrued expenses	2,638,308	3,157,386
Accrued compensation	875,096	298,173
Paycheck protection program loan	324,979
Lease liabilities - current	112,294	121,075
Total current liabilities	6,080,521	6,312,076
Non-current liabilities:
Convertible debt, net	9,859,739
Paycheck protection program loan	92,851
Lease liabilities, net of current	116,296	6,149
Total liabilities	16,149,407	6,318,225
Commitments and contingencies
Shareholders’ equity:
Preferred stock: 350,000 shares authorized; none issued or outstanding
Common stock, $.001 par value; 75,000,000 and 50,000,000 shares authorized; 30,643,656 and 21,753,124 shares issued and outstanding at December 31, 2020 and 2019, respectively	30,644	21,753
Additional paid-in capital	196,949,655	177,006,004
Accumulated other comprehensive loss	(24,337)	(45,010)
Accumulated deficit	(193,214,134)	(175,525,612)
Total shareholders’ equity	3,741,828	1,457,135
Total liabilities and shareholders’ equity	$ 19,891,235	$ 7,775,360